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Abstract. Diabetes arises when insulin secretion is
inadequate for the prevailing metabolic conditions.
As such appropriate measurement of B-cell function is
necessary for a better understanding of the pathophys-
iology of prediabetes and diabetes. Unfortunately this
is not a straightforward process and requires utilization
of mathematical modelling to best appreciate its
complexities. This is because insulin concentrations in
the plasma represent a balance between the processes
of secretion, hepatic extraction and clearance. In
isolation such simple measures reveal very little about
B-cell function. Moreover, since insulin lowers glucose
accounting for the effect of the former on the latter it is
a key part of understanding insulin action. The devel-
opment of the minimal model has allowed simultaneous
measurement of the dynamic relationship between
insulin secretion and insulin action and produces a
quantitative number – the Disposition Index – which
quantifies B-cell function. At present this remains the
best functional measure of islet health, however, it may
not capture other phenotypes such as B-cell senescence
or the effect of incretin hormones on B-cell function.
Future ongoing development and interaction with
other technologies, such as functional imaging, should
enhance the contribution of this functional testing to
the prevention, treatment and understanding of type 2
diabetes.
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1 Introduction
Diabetes is defined by the presence of elevated fast-
ing and postprandial glucose concentrations, and, in-
deed, currently a fasting glucose of ≥126 mg/dL would
qualify a patient as having diabetes. A fasting glucose
(≤100 mg/dL) is considered to be normal, and the range
in between these two parameters characterizes an in-
termediate, often transitory, state referred to as pre-
diabetes. It is well recognized that individuals with
a higher fasting glucose, have a higher risk of transi-
tioning to diabetes. For example, in a population from
Olmsted County, if fasting glucose is ≥110 mg/dL, but
≤126 mg/dL over 10 years, the risk is 40 % (i.e., 40 % of
that particular population will transition to diabetes)
(Dinneen et al., 1998). This may strike one as being a
particularly high number, but conversely, 60 % of people
in the range of fasting glucose never actually transition
to diabetes. In essence, if you look at the people whose
fasting glucose is ≤100 mg/dL, 10 % of those at 10 years
would have transitioned to diabetes, again implying that
fasting glucose by itself may not necessarily be the best
marker for diabetes risk and also demonstrating that
there is significant heterogeneity of diabetes risk at a
given fasting glucose level. The factors driving the tran-
sition to diabetes are at present not well characterized.
2 Pathophysiology of Diabetes:
Defects in Insulin Secretion
and Action
As already mentioned, diabetes is characterized by a
fasting glucose which is elevated after a meal challenge.
Glucose rises to higher concentrations and stays elevated
for a lot longer than it does in normal non-diabetic in-
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dividuals. This elevation in glucose over time is what
leads to diabetes complications. Why does this arise?
It arises because fasting insulin concentrations are inap-
propriate for the prevailing degree of glycaemia. Also,
in response to a meal challenge, insulin concentrations
rise to a lower peak and take a long time getting to
that peak compared to the ten-fold elevation in insulin
concentrations that occurs within about 30-45 minutes
of meal ingestion in non-diabetic individuals. In addi-
tion to delayed and defective insulin secretion, people
with type 2 diabetes inappropriately suppress glucagon
in response to meal ingestion. In fact, a paradoxical
rise in glucagon is often present, in contrast to glucagon
suppression observed in the first two hours after meal
ingestion that is seen in non-diabetic individuals. This
further exacerbates postprandial hyperglycemia (Butler
and Rizza, 1991).
Diabetes is also characterized by defects in insulin ac-
tion (i.e. the ability of insulin to suppress endogenous
production of glucose and to stimulate the peripheral
uptake of glucose in insulin-sensitive tissues is impaired
when compared to non-diabetic individuals). How im-
portant is the interaction of defects in insulin secretion
with defects in insulin action? To address this question,
when people with varying degrees of insulin action are
studied, worsening defects in insulin secretion cause far
greater rises in glucose concentration than either defect
alone, with such effects most marked in people with type
2 diabetes. For example, Basu et al. (1996) studied three
groups of people with varying grades of insulin resistance
(i.e. one group comprised insulin-sensitive, lean, non-
diabetic individuals. Another group comprised insulin-
resistant people with type 2 diabetes, and in a third
intermediate group were obese non-diabetic individuals
who had milder degrees of insulin resistance). These
individuals were studied on two occasions in the pres-
ence of a pancreatic clamp with somatostatin to inhibit
endogenous insulin secretion and with glucagon-growth
hormone replacement at basal concentrations. Subjects
then received a ‘diabetic’ insulin profile (i.e. a decrease
in delayed insulin infusion which mimicked postprandial
response of insulin seen in diabetic individuals) versus
a normal non-diabetic insulin profile. In all subjects,
infusion of a ‘diabetic’ insulin profile in comparison to
the ‘non-diabetic’ profile resulted in higher glucose con-
centrations, but the effect was most marked in the more
insulin-resistant individuals. This implies that, in real-
ity, if insulin action is sufficient, defects in insulin se-
cretion can be compensated for. However, with varying
degrees of insulin resistance, the hyperglycemia that oc-
curs in response to a diabetic insulin profile increases
(Basu et al., 1996).
These observations, in a sense, dispute the previous
prevailing theory of predisposition to diabetes, which
hypothesized that people secrete insulin increasingly
in response to increasing degrees of insulin resistance.
However, there comes a time when the beta cells col-
lectively cannot sustain this increased rate of insulin se-
cretion and hyperglycemia develops (DeFronzo, 1988).
This theory has also been called the Starling’s curve
of the pancreas, taking its cue from the Starling curve
as it applies to the heart where increasing degrees of
preload increase contractility of the myocardium up to
the point of cardiac failure. In practice, this is unlikely
to occur, because across populations of individuals with
prediabetes, it seems that with worsening degrees of hy-
perglycemia insulin secretion and action both decline
concurrently, rather than insulin secretion increasing,
as insulin action decreases and then suddenly failing
(Sathananthan et al., 2012)
3 Measuring Insulin Secretion in
vivo
The original proposition of a Starling Curve of the
pancreas is likely flawed because it is based on popula-
tion cross-sectional data with no longitudinal follow-up.
In addition, most of the calculations used to quantify in-
sulin secretion in response to a standardized meal chal-
lenge used qualitative peripheral insulin concentrations.
It is important to remember that insulin concentrations
alone do not necessarily reflect insulin secretion. The in-
sulin concentrations that appear in the peripheral circu-
lation have already gone through hepatic extraction and
therefore do not necessarily reflect the concentrations of
insulin appearing in the portal circulation as a result
of insulin secretion. Thus the insulin concentrations pe-
ripherally represent the net sum of two processes–insulin
secretion and hepatic extraction (Rossell et al., 1983).
Therefore, for quantitative measures of insulin secretion,
current state-of-the art measurements utilize C-peptide
which is secreted in a 1:1 molar ratio with insulin. The
problem with this approach is that while insulin has a
half-life of ∼ 5 minutes in the circulation, C-peptide
has a half-life of ∼ 35 minutes and tends to accumulate
over time. Therefore to calculate insulin secretion rates,
insulin secretion needs to be deconvoluted from the C-
peptide concentrations using known rates of clearance
for C-peptide (Cobelli et al., 2014).
The other observation to consider is that insulin se-
cretion in response to a physiologic or supraphysiologic
challenge arises from two distinct compartments. This
phenomenon was first observed in isolated islets and
then subsequently in perfused pancreata, where it was
clear that exposure to glucose acutely results in a rapid
upstroke in insulin concentrations, which is then rapidly
followed by a second upstroke which is more sustained
than the first, but whose amplitude is lower. These are
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collectively referred to as the first and second phases
of insulin secretion. The first phase of insulin secre-
tion represents a pool of insulin that is already present
in granules during fasting and is released immediately
in response to hyperglycemia. In contrast, the second
phase of insulin secretion likely represents the synthe-
sis and secretion of insulin in response to sustained hy-
perglycemia. This phenomenon has subsequently been
shown in rodents, primates and in humans in response
to intravenous glucose challenges. However, this bipha-
sic pattern of insulin secretion is actually not observed
in response to oral glucose challenges, likely because of
the effects of hepatic extraction, the magnitude of which
differs in response to the first and second phase of insulin
secretion (Nesher and Cerasi, 2002).
Figure 1: The nature of the hyperbolic relationship be-
tween B-cell responsivity (Φ) and Insulin action (Si) depend-
ing on the glucose tolerance status of an individual. NGT =
Normal Glucose Tolerance, IGT = Impaired Glucose Toler-
ance, DM = Diabetes Mellitus.
4 The Minimal Model
Reproducible, optimal, and quantitative measures of
insulin secretion require some form of modeling which
takes into account the fact that insulin is secreted into
a remote compartment (i.e. the portal vein which is
not accessible for peripheral sampling) and that between
its appearance in the portal vein and its appearance in
the systemic circulation there is a time lag to account
for the distribution of insulin across various tissues and
compartments. This is required because sampling in
the peripheral circulation does not necessarily represent
what is occurring at that time in the portal circulation
in response to a given challenge. The current minimal
model assumes that the sample pool of insulin differs
slightly but significantly from the actively circulating
pool of insulin and, again, this differs from the pool of
insulin which is actually released. The minimal model
also takes into account the delay (otherwise known as
time, T) between the first and second phase of insulin
secretion which represents the time to stimulate insulin
synthesis in response to a given stimulus (Breda et al.,
2001, 2002; Man et al., 2002).
The other consideration when measuring insulin se-
cretion is to take into account the fact that insulin se-
cretion occurs in the context of the prevailing insulin
action. Just as it is unreasonable to talk about power
in engineering terms without taking into account the
amount of weight the said power needs to move, the
same applies for beta cell function, and in such circum-
stances, insulin secretion should be expressed as a func-
tion of the prevailing insulin action. The resulting dis-
position index is currently considered the gold-standard
measure of B-cell function. The disposition index tends
to decrease across the spectrum of prediabetes, and the
lower the disposition index, the likelier the risk of devel-
oping diabetes in the subsequent decade (Cobelli et al.,
2014; Xiang et al., 2014).
Insulin secretion is related to insulin action via a hy-
perbolic relationship so that when glucose tolerance is
maintained, even small decreases in insulin action are
associated with a very significant increase in insulin se-
cretion in an effort to maintain euglycaemia provided
beta cell function is intact. The hyperbolic curve, which
describes this relationship, will shift to the left as the
beta cell fails and an individual becomes diabetic. Ex-
perimentally this paradigm has been proven in multiple
situations, either by using pharmacotherapy or lifestyle
intervention to improve insulin action with a commensu-
rate offloading in insulin secretion or conversely making
individuals acutely insulin resistant using various inter-
ventions such as free fatty acid elevation or niacin to in-
crease insulin secretion, assuming euglycaemia is main-
tained in such circumstances (Bergman, 1989; Bergman
et al., 2002).
The concept of the disposition index has been criti-
cized more recently because of the realization that some
individuals may not actually be able to respond by in-
creasing insulin secretion in the presence of very signif-
icant changes in insulin action, and therefore, a hyper-
bolic relationship may not always exist. Indeed, efforts
are now underway to perhaps better characterize the
nature of the relationship between secretion and action
in a given individual. How this relationship progresses
over time, and whether genetic predisposition or disease
itself actually accounts for a lot of these changes is, at
present, uncertain (Ferrannini and Mari, 2004).
Another important reason for using an oral challenge
over an intravenous glucose challenge to measure beta
cell function is because it incorporates the incretin con-
tribution to insulin secretion (Campioni et al., 2007).
5 What is the incretin effect?
It has long been known by physiologists that for a
given glucose load administered intrajejunally as op-
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Figure 2: The relationship between B-cell responsivity (Φ) and Insulin action (Si) and Disposition Index (DI) across the spectrum
of impaired fasting glucose (left panel) and across the spectrum of impaired glucose tolerance (right panel). NFG = Normal Fasting
Glucose, NGT = Normal Glucose Tolerance, IGT = Impaired Glucose Tolerance, DM = Diabetes Mellitus.
posed to intravenously, despite lower glucose concen-
trations, insulin secretion is far higher. Because of
this, the existence of a gut hormone that stimulates in-
sulin secretion and glucose disposal was hypothesized.
The observed effect has been termed the ‘incretin ef-
fect’ because of its effect in assimilating an oral chal-
lenge (Mcintyre et al., 1964). The subsequent obser-
vation that several segments of the intestine stained
for glucagon and the realization that this was confined
to enteroendocrine cells helped propel the discovery of
Glucagon-like Peptide-1 (GLP-1). The intestine is char-
acterized by cellular heterogeneity and a distinct popu-
lation of cells, characterized as APUD cells (since they
take up amine precursors and decarboxylate them) that
actively secrete multiple gut hormones. The glucagon-
staining cells today are called L cells, and in actual fact,
the immunoreactivity for glucagon arises not because
they contain glucagon but because they contain a frag-
ment of proglucagon, GLP-1. GLP-1 arises from tran-
scription and translation of the glucagon gene to pro-
duce proglucagon but, whereas in the alpha-cell prohor-
mone convertase 2 converts proglucagon to glucagon, in
the L-cells of the gut prohomone convertase 1 converts
proglucagon to GLP-1. Another product of proglucagon
is glucagon-like peptide-2 (GLP-2). GLP-2 is actually
a growth factor for intestinal epithelial cells and has
no effect on insulin secretion or glucose metabolism. A
larger fragment of proglucagon, oxyntomodulin, has ef-
fects on appetite, but its effects are probably not very
significant in normal physiologic circumstances (Holst
et al., 1994; Holst and Orskov, 2001). Nevertheless,
GLP-1 has excited the interest of endocrinologists be-
cause it is a powerful insulin secretagogue and it stim-
ulates insulin secretion in a glucose-dependent manner
(i.e. insulin secretion will not be stimulated if glucose
concentrations are within normal limits and at fasting
concentrations). Unfortunately, GLP-1 has a very short
half-life in the circulation. Therefore, if GLP-1 is to
have therapeutic effect in people with diabetes, it will
need to be infused on a continuous basis, given that its
half-life is on the order of 1-2 minutes. GLP-1 activity
depends on the integrity of the two end-terminal amino
acids, loss of which inactivates GLP-1. An alternative is
to inhibit the main enzyme responsible for its degrada-
tion. This enzyme is dipeptidyl-peptidase 4 and, indeed,
dipeptidyl peptidase 4 inhibitors form a new class of
glucose-lowering agents used to treat diabetes (Drucker
and Nauck, 2006).
The third alternative is to use another analog of GLP-
1 capable of stimulating the seven transmembrane helix
GLP-1 receptor, yet resistant to the degradative effects
of DPP-4. Such analogs are often called GLP-1 receptor
agonists and, again, have been shown to have significant
therapeutic viability in the treatment of diabetes.
There are significant differences between these two
classes of agents which help to inform some of the un-
derlying physiology that predisposes to diabetes. DPP-4
inhibitors raise endogenous GLP-1 concentrations, and
in fact, active concentrations of GLP-1 are raised to high
physiologic concentrations with a peak in the 12-20 pM
range. In contrast, the equivalent activity of GLP-1
receptor agonists is probably achieved at GLP-1 con-
centrations of 25-30 pM. Both DPP-4 inhibitors and
GLP-1 receptor agonists lower fasting and postpran-
dial glucose concentrations, which is done by improv-
ing beta-cell function and simulating insulin secretion
for a given glucose concentration. Intriguingly, GLP-1
receptor agonists also have powerful effects on intesti-
nal motility, delaying gastric emptying, stimulating the
nausea centers in the hypothalamus, and decreasing ap-
petite. These effects are not observed with DPP-4 in-
hibitors (Vella et al., 2007).
6 The role of genetics in GLP-1
responsiveness
There are individuals who exhibit differential respon-
siveness to GLP-1-based therapy or GLP-1 infusion.
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The earliest suggestion that this may be genetic in ori-
gin came from Beinborn et al. (2005) who identified a
GLP-1 receptor mutation which altered responsitivity of
the GLP-1 receptor to GLP-1 by about 50 % (Beinborn
et al., 2005). Subsequently, the suggestion that common
genetic polymorphisms in the GLP-1 receptor may affect
responsiveness to infused GLP-1 was tested in a popu-
lation of healthy individuals and indeed, two polymor-
phisms were identified which significantly altered GLP-1
responsitivity. Of the two SNPs identified, the most pro-
found action was observed for RS3765467, which is an
arginine to glutamine change at position 131 of the GLP-
1 receptor in axon 4. This has a minor allele frequency of
5 % in Caucasians and, in the particular experiment, had
a very profound effect on insulin secretion in response
to infused GLP-1 and glucose. In contrast, RS6923761
results in a glycine to serine substitution at position 168
in axon 5. This has a minor allele frequency of about
30 % in Caucasian and, indeed, the individuals who are
homozygous for serine at that position have decreased
responsiveness to GLP-1 compared to the more com-
mon form where individuals are homozygous for glycine
(Sathananthan et al., 2010).
7 GLP-1 and bariatric surgery
Another way that GLP-1 may be potentially impor-
tant in diabetes is as it pertains to bariatric surgery.
The commonest form of bariatric surgery undertaken, at
least in North America, currently is Roux-en-Y gastric
bypass, which creates a small restrictive gastric pouch
and diverts nutrients to the distal intestine. The effect of
distal delivery of calories results in stimulation of GLP-
1 secretion. Individuals after gastric bypass have high
concentrations of GLP-1 in response to meal ingestion
(Laferre`re et al., 2008). Roux-en-Y gastric bypass has
aroused interest recently because bypass operations are
associated with remission of diabetes in about 40 % of all
individuals with type 2 diabetes, and it has been hypoth-
esized that GLP-1 may play a role in this remission. In
such circumstances, one of the experimental paradigms
used to investigate the contribution of endogenous GLP-
1 to insulin secretion in the postprandial period has been
to use competitive antagonist of GLP-1 at its cognate
receptor. This antagonist is exendin-(9,39) and is ac-
tually a derivative of a GLP-1 receptor agonist which
is truncated and, therefore, has no significant metabolic
effect when it binds the GLP-1 receptor.
In non-diabetic patients after Roux-en-Y gastric by-
pass, infusion of exendin-(9,39) results in decreased in-
sulin and C-peptide concentrations compared to age-,
weight-, and gender-matched controls. Indeed, this re-
sults in a small but significant rise in peak and inte-
grated glucose concentrations. These effects are due to
small effects on beta-cell function, as manifested by de-
creases in beta-cell responsitivity. What is interesting
is that the component of beta-cell responsitivity that is
affected is the one that is dependent upon insulin syn-
thesis and secretion in keeping with the known effects
of GLP-1 on insulin synthesis. The converse experimen-
tal administration of GLP-1 or GLP-1-based therapies
raise the component of insulin secretion that is associ-
ated with synthesis and secretion (Shah et al., 2014).
A neglected part of the physiology of insulin secre-
tion is the fact that insulin is actually secreted into the
portal vein in a pulsatile fashion, and the amplitude
and frequency of insulin pulses are decreased in patho-
logic states, such as aging, obesity, and type 2 diabetes.
GLP-1 may be important when secreted into the portal
vein because it may help maintain beta-cell competence
as well as beta-cell pulsatility and amplitude. Whether
fasting and postprandial insulin secretion or its pulsatil-
ity has effects on, for example, hepatic insulin action,
thereby explaining the relationship between insulin se-
cretion and action observed in prediabetes, is as yet un-
known but is the subject of active investigation (Meier
et al., 2005; Matveyenko et al., 2008).
8 Measuring B-cell mass
The final aspect as pertains to beta-cell function is
the quest to try and quantify beta-cell mass. At present,
this subject is problematic. Initial attempts of quanti-
fying beta-cell mass were quite simple and qualitative
as they involved counting islets in autopsy specimens.
Since then attempts have been made to undertake in-
vasive testing in humans using pancreatic biopsy. Un-
fortunately, this method is flawed with complications
and rarely provides useful information, therefore it has
almost been abandoned completely. Efforts have been
made to try and quantify islet mass by extrapolating
from pancreatic volume obtained by conventional, non-
invasive imaging such as CT scanning of magnetic res-
onance imaging and subsequent extrapolation of islet
number. More recently, efforts have been made to use
ligands specific to the islets which then can be labeled
either with a fluorescent marker detectable by noninva-
sive imaging or with a radio-labeled ligand. However, to
date there has been no compound identified which binds
specifically to the islets.
At the current time, the best paradigm for beta-cell
function in vivo is ultimately reductionist in approach;
currently islet numbers and islet morphology are less im-
portant than how they function in response to a given
challenge. It is in this circumstance that a functional
test such as an oral glucose tolerance test or a mixed
meal test and subsequent mathematical extrapolation
of beta-cell function may be important clinically. Our
current therapeutic interventions are intended to im-
prove glycaemic control not improving beta-cell health.
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Nevertheless, using the current mathematical models to
quantify beta-cell function over time may have thera-
peutic application in the near future with the develop-
ment of novel therapeutics intended to increase beta-cell
mass and function.
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